# Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

> **NCT04007978** · PHASE1 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 50 (estimated)

## Conditions studied

- B Cell Lymphoma
- Acute Lymphoblastic Leukemia

## Interventions

- **GENETIC:** Third generation CAR-T cells

## Key facts

- **NCT ID:** NCT04007978
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-05
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04007978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04007978, "Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04007978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*